VRTX (Vertex Pharmaceuticals Inc)
Insider Trading Activity
Every open-market purchase and sale reported by VRTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-23 | Amit Sachdev | EVP Chief Patient & Ext Af Off | A | — | — |
| 2026-07-23 | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | A | — | — |
| 2026-07-17 | Alan M Garber | Director | A | — | — |
| 2026-07-17 | BRUCE I SACHS | Director | A | — | — |
| 2026-07-07 | Duncan McKechnie | EVP, Chief Commercial Officer | Sell | — | — |
| 2026-07-07 | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | Sell | — | — |
| 2026-07-06 | Joy Liu | EVP and Chief Legal Officer | Sell | — | — |
| 2026-06-23 | Carmen Bozic | EVP and CMO | Sell | — | — |
| 2026-06-17 | Carmen Bozic | EVP and CMO | Sell | — | — |
| 2026-06-09 | Carmen Bozic | EVP and CMO | Sell | — | — |
| 2026-06-03 | Joy Liu | EVP and Chief Legal Officer | Sell | — | — |
| 2026-06-02 | Carmen Bozic | EVP and CMO | Sell | — | — |
| 2026-05-19 | Carmen Bozic | EVP and CMO | Sell | — | — |
| 2026-05-19 | Mark E. Bunnage | EVP, Chief Scientific Officer | Sell | — | — |
| 2026-05-14 | Carmen Bozic | EVP and CMO | Sell | — | — |
| 2026-05-05 | Sangeeta N. Bhatia | Director | MIXED | — | — |
| 2026-05-05 | LLOYD CARNEY | Director | A | — | — |
| 2026-05-05 | Alan M Garber | Director | A | — | — |
| 2026-05-05 | Michel Lagarde | Director | A | — | — |
| 2026-05-05 | Joy Liu | EVP and Chief Legal Officer | Sell | — | — |
| 2026-05-05 | DIANA MCKENZIE | Director | MIXED | — | — |
| 2026-05-05 | BRUCE I SACHS | Director | A | — | — |
| 2026-05-05 | Jennifer Schneider | Director | MIXED | — | — |
| 2026-05-05 | Nancy Thornberry | Director | MIXED | — | — |
| 2026-05-05 | Suketu Upadhyay | Director | D | — | — |
| 2026-04-17 | Alan M Garber | Director | A | — | — |
| 2026-04-17 | BRUCE I SACHS | Director | A | — | — |
| 2026-04-17 | Suketu Upadhyay | Director | A | — | — |
| 2026-04-03 | Joy Liu | EVP and Chief Legal Officer | Sell | — | — |
| 2026-03-31 | Carmen Bozic | EVP and CMO | Sell | — | — |
| 2026-03-17 | Carmen Bozic | EVP and CMO | Sell | — | — |
| 2026-03-13 | Duncan McKechnie | EVP, Chief Commercial Officer | Sell | — | — |
| 2026-03-06 | Duncan McKechnie | EVP, Chief Commercial Officer | Sell | — | — |
| 2026-03-04 | Joy Liu | EVP and Chief Legal Officer | Sell | — | — |
| 2026-03-03 | Carmen Bozic | EVP and CMO | Sell | — | — |
| 2026-03-03 | Reshma Kewalramani | CEO & President | Sell | — | — |
| 2026-03-02 | Kristen Ambrose | SVP & Chief Accounting Officer | Sell | — | — |
| 2026-02-26 | Kristen Ambrose | SVP & Chief Accounting Officer | MIXED | — | — |
| 2026-02-26 | Edward Morrow III Atkinson | EVP, Chief Technical Ops. Off. | MIXED | — | — |
| 2026-02-26 | Jonathan Biller | EVP and Chief Legal Officer | MIXED | — | — |
| 2026-02-26 | Carmen Bozic | EVP and CMO | F | — | — |
| 2026-02-26 | Mark E. Bunnage | EVP, Chief Scientific Officer | MIXED | — | — |
| 2026-02-26 | Reshma Kewalramani | CEO & President | F | — | — |
| 2026-02-26 | JEFFREY M LEIDEN | Executive Chairman | F | — | — |
| 2026-02-26 | Duncan McKechnie | EVP, Chief Commercial Officer | MIXED | — | — |
| 2026-02-26 | Amit Sachdev | EVP Chief Patient & Ext Af Off | MIXED | — | — |
| 2026-02-26 | Ourania Tatsis | EVP, Chief Reg. & Quality Off. | MIXED | — | — |
| 2026-02-26 | CHARLES F JR WAGNER | EVP, CO & FO | F | — | — |
| 2026-02-23 | Amit Sachdev | EVP Chief Patient & Ext Af Off | MIXED | — | — |
| 2026-02-19 | Kristen Ambrose | SVP & Chief Accounting Officer | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | SVP & Chief Legal Officer | 309,166 | — |
| — | Director | 297,374 | — |
| — | Executive Chairman | 200,873 | — |
| — | EVP, Global R&D, CSO | 165,538 | — |
| — | EVP, Med. Dev. Group & CMO | 146,185 | — |
| — | CEO & President | 127,596 | — |
| — | EVP, Strategic & Corp. Devlp. | 101,384 | — |
| — | EVP, COO | 75,380 | — |
| — | EVP Chief Patient & Ext Af Off | 73,149 | — |
| — | EVP & Chief Legal Officer | 72,419 | — |
| — | EVP GMDA, CMO | 72,385 | — |
| — | EVP, COO | 63,508 | — |
| — | EVP, Chief Commercial Officer | 60,485 | — |
| — | EVP, Chief Reg. & Quality Off. | 53,572 | — |
| — | EVP, Medicines Development | 53,334 | — |
| — | EVP, CO & FO | 47,042 | — |
| — | Director | 45,000 | — |
| — | SVP, Corp. Communications | 43,350 | — |
| — | SVP, Corp Strategy & Bus Devlp | 42,776 | — |
| — | SVP and Catalyst | 38,782 | — |
| — | Executive Chairman | 35,237 | — |
| — | EVP, Cell & Genetic Therapies | 34,888 | — |
| — | SVP, Human Resources | 34,525 | — |
| — | EVP, Chief Commercial Officer | 32,232 | — |
| — | Director | 31,750 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VRTX quote page; the site-wide leaderboard is on the insider transactions hub.